Benevolent Platform Precision Medicine slide image

Benevolent Platform Precision Medicine

250 200 150 aSyn area/TH neurons (% of control, TH) 100 50 Control MPP+ 4UM/48h 100- 80- TH number (% of control) 60- 40- 20- Abl inhibitor is neuroprotective in in vitro Parkinson's MMP+ induced TH neuron toxicity and a-synuclein aggregation in mouse primary dopaminergic neuron cultures' 120 disease and ALS models Tunicamycin induced apoptosis of sporadic ALS patient iPSC derived motor neurons² 8.0x 105- Glutamate induced apoptosis of sporadic ALS patient iPSC derived motor neurons² 8.0x 10- Control Control MPP+ 4μM/48h (10 nM) (30 nM) (100 nM)' (300 nM) (1 μM) (3 µM) (10 µM) Ben-B (10 nM) (30 nM) (100 nM) (300 nM) (1 μM) (3 μM) (10 μM) + BDNF (50 ng/mL) + BDNF (50 ng/mL) Total Red Object Area (μm²/Well) 6.0x 105- 4.0x 105- 2.0x 105- 8.0x 105- 6.0x105- 0 T Total Red Object Area (μm²/Well) 4.0x 105- 2.0x105- Ben-B 'Data from Neurosys. 2Data from iXcell (both CROS are engaged by the Company to provide services for this programme) No Stim Ctrl Tunicamycin 10 μM 50 100 150 200 250 Time (h) *** ** Ben-B 1 μM 0.1 M 0.01 μM No Stim Ctrl Tunicamycin -10 μM 1 μM -0.1 μM -0.01 μM Total Red Object Area (μm²/Well) 6.0x 105- 4.0x 105- 2.0x 10- 8.0×105- 6.0x105- Total Red Object Area (μm²/Well) 4.0×105- 2.0x105- 0+ 0 50 100 150 200 250 Time (h) No Stim Ctrl Glutamate 10 μM *** *** **** T 1 μM > 0.1μM 0.01μM Ben-B Benevolent 49 Glutamate 10 μM 1 μM 0.1μM 0.01 μM
View entire presentation